炎症性肠病患者从英夫利西单抗原研药转换为生物类似药的12个月多中心观察性前瞻性队列研究
该多中心观察性前瞻性队列研究纳入两家医院的133例成人炎症性肠病患者,将英夫利西单抗原研药(Remicade)转换为生物类似药(Inflectra)作为常规诊疗的一部分。转换后12个月内35例(26%)停药,主要因主观感觉疾病活动度升高(9%)和不良事件(9.8%);四个时间点的英夫利西单抗谷浓度、CRP和疾病活动度评分均无差异(P≥.0917)。作者认为生物类似药安全有效。
要点
- 133例IBD患者从英夫利西单抗原研药转换为生物类似药,12个月内26%停药,多因主观疾病加重或不良事件。
- 转换后四个时间点英夫利西单抗谷浓度、CRP和疾病活动度评分无差异(P≥.0917)。
- 作者认为生物类似药在IBD患者中安全有效。
核心结论
- 作者结论:在本IBD队列中,英夫利西单抗原研药与生物类似药在药物浓度和疾病活动度方面无差异,表明生物类似药安全有效。
- 停药比例较高主要由于选择性停药或主观疾病加重。
研究设计与样本
- 多中心观察性前瞻性队列研究,纳入两家医院的133例成人IBD患者(64%为克罗恩病,36%为溃疡性结肠炎)。
- 患者作为常规诊疗的一部分从英夫利西单抗原研药(Remicade)转换为生物类似药(Inflectra),但在受控环境中进行。
- 在生物类似药第1、2、4和7次输注前采血,检测英夫利西单抗谷浓度、抗英夫利西单抗抗体(ATI)、CRP和ESR,并计算疾病活动度评分;随访12个月。
主要发现
- 转换前英夫利西单抗水平差异很大(中位数3.5 μg/mL),8例患者(6%)检测到ATI。
- 多数患者处于缓解期或疾病轻度(克罗恩病82%,溃疡性结肠炎90%)。
- 转换后12个月内35例患者(26%)停药,主要原因为主观感觉疾病活动度升高(9%)和不良事件(9.8%)。
- 不良事件包括全身乏力/疲劳(n=7)、关节痛(n=2)、皮肤问题(n=2)和输注反应(n=2)。
- 四个时间点之间英夫利西单抗水平、CRP和疾病活动度评分均无差异(P≥.0917)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infliximab biosimilars have become available for treatment of inflammatory bowel disease (IBD). However, data showing long-term safety and effectiveness of biosimilars in IBD patients are limited. AIM: To study prospectively the switch from infliximab innovator to biosimilar in an IBD cohort with 12 months follow-up to evaluate safety and effectiveness. METHODS: Adult IBD patients from two hospitals treated with infliximab innovator (Remicade; Janssen Biotech, Horsham , Pennsylvania, USA) were switched to infliximab biosimilar (Inflectra; Hospira, Lake Forest, Illinois, USA) as part of routine care, but in a controlled setting. Blood samples were taken just before the first, second, fourth and seventh infusion of biosimilar. Infliximab trough levels, antibodies-to-infliximab (ATI), CRP and ESR were measured and disease activity scores were calculated. RESULTS: Our cohort consisted of 133 IBD patients (64% CD, 36% UC). Before switching we found widely varying infliximab levels (median 3.5 μg/mL). ATI were detected in eight patients (6%). Most patients were in remission or had mild disease (CD: 82% UC: 90%). After switching to biosimilar, 35 patients (26%) discontinued therapy within 12 months, mostly due to subjective higher disease activity (9%) and adverse events (AE, 9.8%). AE included general malaise/fatigue (n = 7), arthralgia (n = 2), skin problems (n = 2) and infusion reactions (n = 2). No differences in IFX levels, CRP, and disease activity scores were found between the four time points (P ≥ .0917). CONCLUSIONS: We found no differences in drug levels and disease activity between infliximab innovator and biosimilar in our IBD cohort, indicating that biosimilars are safe and effective. The high proportions of discontinuers were mostly due to elective withdrawal or subjective disease worsening.
引用
- Schmitz EMH, Boekema PJ, Straathof JWA, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2017. PMID: 29205444. doi:10.1111/apt.14453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。